MGNX
Closed
Macrogenics Inc
1.26
+0.05 (+4.13%)
Last Update: 01 Jul 2025 23:00:00
Yesterday: 1.21
Day's Range: 1.19 - 1.325
Send
sign up or login to leave a comment!
When Written:
7.34
MacroGenics Inc is a biopharmaceutical company that focuses on the discovery and development of innovative medicines for the treatment of cancer and autoimmune diseases. The company was founded in 2000 and is headquartered in Rockville, Maryland.
MacroGenics has a diverse pipeline of product candidates, including both biologics and small molecules. Its lead product candidate is margetuximab, a monoclonal antibody being developed for the treatment of HER2-positive breast cancer. The company also has several other product candidates in clinical development for various indications, including solid tumors and hematological malignancies.
In addition to its proprietary product candidates, MacroGenics has collaborations with several pharmaceutical companies, including Incyte and Janssen Biotech, to develop and commercialize novel therapies.
MacroGenics has a strong research and development team, with expertise in antibody engineering, protein biochemistry, and immunology. The company has also received recognition for its innovative technology platforms, including its DART and TRIDENT bispecific antibody platforms.
As of 2021, MacroGenics had approximately 500 employees and a market capitalization of over $1 billion.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
MacroGenics has a diverse pipeline of product candidates, including both biologics and small molecules. Its lead product candidate is margetuximab, a monoclonal antibody being developed for the treatment of HER2-positive breast cancer. The company also has several other product candidates in clinical development for various indications, including solid tumors and hematological malignancies.
In addition to its proprietary product candidates, MacroGenics has collaborations with several pharmaceutical companies, including Incyte and Janssen Biotech, to develop and commercialize novel therapies.
MacroGenics has a strong research and development team, with expertise in antibody engineering, protein biochemistry, and immunology. The company has also received recognition for its innovative technology platforms, including its DART and TRIDENT bispecific antibody platforms.
As of 2021, MacroGenics had approximately 500 employees and a market capitalization of over $1 billion.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!








